Template:Short description Template:Drugbox
Abarelix, sold under the brand name Plenaxis, is an injectable gonadotropin-releasing hormone antagonist (GnRH antagonist) which is marketed in Germany and the Netherlands. It is primarily used in oncology to reduce the amount of testosterone made in patients with advanced symptomatic prostate cancer for which no other treatment options are available.<ref name="Drugs.com-2">{{#invoke:citation/CS1|citation |CitationClass=web }}</ref><ref>Template:Cite journal</ref>
It was originally marketed by Praecis Pharmaceuticals as Plenaxis,<ref name="Drugs.com-2" /> and is now marketed by Speciality European Pharma in Germany<ref>Pharmazeutische Zeitung online: Abarelix Template:In lang</ref> after receiving a marketing authorization in 2005. The drug was introduced in the United States in 2003, but was discontinued in this country in May 2005 due to poor sales and a higher-than-expected incidence of severe allergic reactions.<ref name="Minev2011">Template:Cite book</ref> It remains marketed in Germany and the Netherlands however.<ref name="Drugs.com">{{#invoke:citation/CS1|citation |CitationClass=web }}</ref>
See alsoEdit
ReferencesEdit
Template:GnRH and gonadotropins Template:GnRH and gonadotropin receptor modulators